NDLI: Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis

Please wait, while we are loading the content...

A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy

Outcome of Epstein-Barr virus-associated primary breast cancer

Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer

Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios

Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis

Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed

Vascular endothelial growth factor polymorphisms as effect modifiers of oral squamous cell carcinoma risk: A systematic review and meta-analysis

Prognostic value of osteopontin expression in breast cancer: A meta-analysis

Patient age, tumor appearance and tumor size are risk factors for early recurrence of cervical cancer

Fertility following treatment of high-grade malignant bone and soft tissue tumors in young adults

Year: 2015, Volume: 3, Issue: 1

Year: 2014, Volume: 3

Year: 2014, Volume: 2

Year: 2013, Volume: 2

Year: 2013, Volume: 1

Year: 2012, Volume: 1

Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis

Content Provider	PubMed Central
Author	Akita, Hirofumi Shigeru, Marubashi Wada, Hiroshi Hama, Naoki Kawamoto, Koichi Kobayashi, Shogo Eguchi, Hidetoshi Doki, Yuichiro Mori, Masaki Nagano, Hiroaki
Copyright Year	2015
Abstract	Managing extrahepatic recurrence in hepatocellular carcinoma (HCC) patients is crucial for improving prognosis. The present study aimed to investigate the effectiveness of using combination therapy with S-1 and interferon (IFN)- α in HCC patients with lung metastasis. Of the 646 patients who underwent radical surgery for HCC at our institute, 62 developed their first distant metastasis in the lung. Among these patients, 11 received S-1 combination therapy, while the remaining 51 patients received other conventional therapy, such as 5-fluorouracil and cisplatin or best supportive care. We retrospectively evaluated the toxicity and efficiency of combination therapy with S-1 and IFN- α. Hematological toxicity was observed in 5 patients and was grade 1 or 2 in all cases, except 1 patient (9.1%) who developed grade 3 leukopenia. Non-hematological toxicity was observed in 6 patients and was grade 1 in all cases, except 1 patient who exhibited a grade 2 increase of serum bilirubin levels. No patient required discontinuation of the S-1 combination therapy and no treatment-related mortality was reported during this study. Patients who received S-1 treatment exhibited significantly better survival after distant recurrence (SADR) compared to those without S-1 treatment (3-year survival rate, 81.8 vs. 43.1%, respectively; P=0.014). The multivariate analysis revealed that the S-1 treatment was prognostically significant for SADR (P=0.0091; hazard ratio = 0.343). In conclusion, combination therapy with S-1 and IFN- α may be efficient for HCC patients with lung metastasis.
Related Links	http://dx.doi.org/10.3892/mco.2014.463
Ending Page	328
Page Count	7
Starting Page	322
File Format	PDF
ISSN	20499469
e-ISSN	20499469
Journal	Molecular and Clinical Oncology
Issue Number	2
Volume Number	3
Language	English
Publisher	D.A. Spandidos
Publisher Date	2015-03-01
Access Restriction	Open
Rights Holder	D.A. Spandidos
Subject Keyword	Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Successful Outcomes Using Combination Therapy of Interleukin-2 and Interferon-α for Renal Cell Carcinoma Patients with Lung Metastasis

Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression

Activation of Wnt/β-catenin signalling pathway induces chemoresistance to interferon-α/5-fluorouracil combination therapy for hepatocellular carcinoma

Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?

Plasma level of metastasis‐associated lung adenocarcinoma transcript 1 is associated with liver damage and predicts development of hepatocellular carcinoma

Interferon-α enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma

Increasing Incidence of Brain Metastasis in Patients with Advanced Hepatocellular Carcinoma in the Era of Antiangiogenic Targeted Therapy

Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?

Elevated Src expression associated with hepatocellular carcinoma metastasis in northern Chinese patients

Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis

Similar Documents

Successful Outcomes Using Combination Therapy of Interleukin-2 and Interferon-α for Renal Cell Carcinoma Patients with Lung Metastasis

Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression

Activation of Wnt/β-catenin signalling pathway induces chemoresistance to interferon-α/5-fluorouracil combination therapy for hepatocellular carcinoma

Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?

Plasma level of metastasis‐associated lung adenocarcinoma transcript 1 is associated with liver damage and predicts development of hepatocellular carcinoma

Interferon-α enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma

Increasing Incidence of Brain Metastasis in Patients with Advanced Hepatocellular Carcinoma in the Era of Antiangiogenic Targeted Therapy

Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?

Elevated Src expression associated with hepatocellular carcinoma metastasis in northern Chinese patients

Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis